Goldman Sachs’s AEON Biopharma AEON Stock Holding History

Goldman Sachs’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-157	Closed	-$11.9K	–	5797
2024 Q2	$11.9K	Sell	157 -2,192	-93%	-$522K	﹤0.01%	5536
2024 Q1	$1.96M	Buy	2,349 +2,091	+810%	+$1.51M	﹤0.01%	3878
2023 Q4	$134K	Sell	258 -80	-24%	-$32.1K	﹤0.01%	5243
2023 Q3	$136K	Buy	+338	New	+$155K	﹤0.01%	5127
2023 Q1	–	Sell	-3,854	Closed	-$2.79M	–	5889
2022 Q4	$2.79M	Hold	3,854	–	–	﹤0.01%	3671
2022 Q3	$2.73M	Hold	3,854	–	–	﹤0.01%	3696
2022 Q2	$2.72M	Hold	3,854	–	–	﹤0.01%	3767
2022 Q1	$2.71M	Hold	3,854	–	–	﹤0.01%	3957
2021 Q4	$2.69M	Hold	3,854	–	–	﹤0.01%	3986
2021 Q3	$2.7M	Sell	3,854 -2	-0.1%	-$1.4K	﹤0.01%	3916
2021 Q2	$2.68M	Buy	+3,856	New	+$2.7M	﹤0.01%	3936

Other funds holding AEON

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Caprock Group Boise, Idaho $5.22B AUM 42.47% 1-Year Est. Return

Goldman Sachs's AEON Position: Q3 2024 in Review

Goldman Sachs sold out of AEON Biopharma (AEON) in Q3 2024, closing a stake of 157 shares — an estimated $11.9K sold.

Goldman Sachs first reported a position in AEON in Q2 2021 and held it in 11 quarters. The position peaked at $2.79M in Q4 2022. 30 funds tracked by Wall St. Rank hold AEON as of Q3 2024.

Goldman Sachs reported no remaining AEON Biopharma position as of Q3 2024 after selling out during the quarter.
Goldman Sachs sold 157 AEON Biopharma shares in Q3 2024, an estimated $11.9K.
Goldman Sachs first reported a position in AEON Biopharma in Q2 2021 and held it in 11 quarters.
Goldman Sachs's AEON Biopharma position peaked at $2.79M in Q4 2022.
30 funds tracked by Wall St. Rank held AEON Biopharma as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.